1.Comparison of cyclosporine concentrarions in whole blood of renal transplant patients:radioimmunoassay with a specific monoclonal antibody and 3H-and 125I-labeled ligand.
Jin Hyung KIM ; Seung Ryeol RHEE
Journal of the Korean Surgical Society 1993;45(5):840-848
No abstract available.
Cyclosporine*
2.A case of dermatomyositis remitted with cyclosporin A.
Jo Won JUNG ; Ki Soo PAI ; Pyung Kil KIM ; Woo Hee JUNG
Journal of the Korean Pediatric Society 1992;35(3):399-405
No abstract available.
Cyclosporine*
;
Dermatomyositis*
3.Evaluation of nephrotoxicity of cyclosporin a treatment in pediatric nephrotic patients.
Young Jin LEE ; Hae Ok ROH ; Pyung Kil KIM ; Hyun Joo JEONG ; In Joon CHOI
Korean Journal of Nephrology 1993;12(4):557-565
No abstract available.
Cyclosporine*
;
Humans
4.Pharmacokinetics of oral cyclosporine A microemulsion, Noeral®, in Vietnamese healthy volunteers
Journal Ho Chi Minh Medical 2005;9(3):181-188
The study was carried out on 30 healthy volunteers (16 males, 14 females), aged 21-40. Cyclosporine A (CsA), Neoral®, dosage of 2 mg/kg body weight (rounded nearest to 25 mg), was given at hours as 0 (starting time), 12, and 24. The blood samples were collected at hours 0, 2, 4, 6, 8, 12 (before the 2nd dose), 24 (before the 3rd dose) and 36. The CsA concentrations were measured with fluorescence polarization immunoassay (FPIA) with the TDx analyser, Abbott. Results: Pharmacokinetics of CsA, oral micro-emulsion, in Vietnamese volunteers have the characteristics: Cmax = 763 ± 241 ng/ml, Cmin = 358 ± 104 mg/ml/mg/kg, tmax = 2.3 ± 1.1 h, AUC 0-4 = 1756 ± 561 ng.h/ml, AUC0-4 /dose/kg = 827 ± 250 ng.h/ml/mg/kg, AUCinf = 3725 ± 983 ng.h/ml,
AUCinf/dose/kg = 1756 ± 433 ng.h/ml/mg/kg, t1/2 = 4.1 ± 1.2, Cl/F = 30.5 ± 6.9 L/h. The inter-individual variation in pharmacokinetics is presented with the coefficient of variations (CVs) of Cmax, AUC 0-4, AUCinf as 31.6%, 31.9% and 26.4%, respectively. The concentration of C2 has an important linear relationship with AUC0-4 (r = 9.987, p <0.0005), inversely there is no linear relation between C12 (the trough C0: before 2nd dose of CsA) (r = -0.189, p= 0.32). Cmax/dose/kg, AUC0-4/dose/kg and AUCinf/dose/kg in female volunteers were lower than those in male volunteers (p<0.005)
Pharmacokinetics
;
Cyclosporine
5.The Therapeutic Drug Monitoring Consultation on Cyclosporine.
Journal of Laboratory Medicine and Quality Assurance 2008;30(2):237-239
No abstract available.
Cyclosporine
;
Drug Monitoring
6.Vitiligo Lesions Stopped Spreading after Oral Cyclosporine in a Vitiligo Patient Who Shows Systemic Steroid Resistance.
Woong Suk CHAE ; Danbi LEE ; Ha Na JUNG ; Ho Seok SUH ; Yu Sung CHOI
Korean Journal of Dermatology 2014;52(2):144-145
No abstract available.
Cyclosporine*
;
Humans
;
Vitiligo*
7.A Case of Widespread Scleredema Treated with Cyclosporine and Steroid.
Hye Won KIM ; Min Wha CHOI ; Sook Ja SON ; June Hyunkyung LEE ; Tae Young HAN
Korean Journal of Dermatology 2017;55(8):537-538
No abstract available.
Cyclosporine*
;
Scleredema Adultorum*
8.Chronic Cyclosporine Nephrotoxicity in Idiopathic Nephrotic Syndrome of Childhood.
Korean Journal of Nephrology 2002;21(3):362-366
No abstract available.
Cyclosporine*
;
Nephrotic Syndrome*
9.The Effects of Cyclosporin in Treatment of Insulin Dependent Diabetes Mellitus.
Journal of the Korean Pediatric Society 1985;28(6):564-569
No abstract available.
Cyclosporine*
;
Diabetes Mellitus*
;
Insulin*
10.Systemic Treatment of Cyclosporin in Severe Atopic Dermatitis.
Pediatric Allergy and Respiratory Disease 2004;14(1):28-29
No abstract available.
Cyclosporine*
;
Dermatitis, Atopic*
Result Analysis
Print
Save
E-mail